サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1380251

血中循環腫瘍細胞（CTC）の世界市場：2023-2030年

Global Circulating Tumor Cells (CTC) Market 2023-2030

出版日
ページ情報
英文 195 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
血中循環腫瘍細胞（CTC）の世界市場：2023-2030年
出版日: 2023年09月25日
発行: Orion Market Research
ページ情報: 英文 195 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の血中循環腫瘍細胞（CTC）市場は予測期間（2023-2030年）にCAGR 12.5％で成長すると予測されます。血中循環腫瘍細胞（CTC）（CTC）は、早期発がん、がんの進行、治療効果に関する血液バイオマーカーとなります。CTCアッセイの採用が拡大していることは、疾病管理を支援するバイオマーカーとして強い関心を集めており、世界の市場成長を支える重要な要因として作用しています。様々な検査は、特に循環腫瘍モニタリングアッセイでは、簡単な採血で患者の治療に対する反応を連続的にモニタリングする能力を医師に提供し、それらの知見を将来の治療のための情報に基づいた意思決定に役立てることができます。したがって、市場参入企業は、市場成長をさらに強化する血中循環腫瘍細胞（CTC）ベースのモニタリングアッセイの導入にも注力しています。例えば、2023年1月、がんの分子プロファイリングのFoundation Medicine, Inc.と無細胞DNA検査のNatera, Inc.は、個別化循環腫瘍DNA（ctDNA）モニタリングアッセイであるFoundationOne（R）Trackerの臨床使用のための早期アクセスプログラムを開始しました。

セグメント別展望

キットと試薬のサブセグメントが世界の血中循環腫瘍細胞（CTC）市場でかなりのシェアを占めると予想されます。

製品の中でも、キットと試薬のサブセグメントが世界の血中循環腫瘍細胞（CTC）（CTC）市場でかなりのシェアを占めると予想されています。このセグメントの成長は、非侵襲的培養培地キットと試薬ががんの検出において影響力を増していることに起因しています。個々の患者に由来する腫瘍細胞は、研究者が試験管内で疾患をより適切にモデル化し、治療薬に対する患者の反応を予測することを可能にすることで、臨床試験の成功率向上に役立つと期待されています。各社の新しい既製のモジュール式腫瘍培養培地キットは、複雑ながんモデルを研究者がより利用しやすくするように設計されています。例えば、2023年6月、サーモフィッシャーサイエンティフィック社は、複数のがん適応症の患者由来の腫瘍組織（がんオルガノイド）の拡大用に特別に開発された初の市販培地であるGibco（TM）OncoPro（TM）Tumoroid Culture Medium Kit*を発売しました。

地域別展望

世界の血中循環腫瘍細胞（CTC）市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されています。中でもアジア太平洋地域は、CTCベースの検査や非侵襲的な方法など、循環腫瘍の診断に効果的な診断ツールの採用により、かなりのCAGRを維持すると予測されています。主な市場プレイヤーには、AnchorDx社、Burning Rock Biotech Ltd.、Exact Sciences Corp.、Guardant Health社、大塚製薬株式会社などが含まれます。

北米地域が世界の血中循環腫瘍細胞（CTC）市場で優位を占めると予想される

全地域の中で、北米地域が予測期間中に最大の市場シェアを占めると予測されています。この地域の成長は、患者人口が多いこと、主なプレイヤーの存在が大きいこと、薬剤の入手が容易であること、医療インフラが発達していること、医療制度における償還政策が有利であること、研究開発・イノベーション活動が活発であること、高度な血中循環腫瘍細胞（CTC）（CTC）技術の採用が進んでいることなどに起因しています。地域の成長はがん患者の増加に起因します。

米国がん協会（ACS）によると、2023年1月に肺がんの新規患者数は約238,340人（男性117,550人、女性120,790人）、肺がんによる死亡者数は約127,070人（男性67,160人、女性59,910人）です。同地域における主要市場参入企業による投資の増加と、主要企業による様々な戦略の採用の増加は、同市場における機会を増加させると予測されます。主要市場プレイヤーには、Advanced Cell Diagnostics社、Bio-Rad Laboratories社、Epic Sciences社、Ikonisys社、Illumina社などが含まれます。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Bio-Rad Laboratories, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • QIAGEN N.V.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Thermo Fisher Scientific Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Johnson & Johnson Service Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Illumina, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 血中循環腫瘍細胞（CTC）の世界市場：技術別
    • CTC検出および濃縮法
    • CTC直接検出法
    • CTC分析
  • 血中循環腫瘍細胞（CTC）の世界市場：製品別
    • キットおよび試薬
    • 採血管
    • デバイス
  • 血中循環腫瘍細胞（CTC）の世界市場：エンドユーザー別
    • 病院および診療所
    • 診断センター
    • 研究・学術機関

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Advanced Cell Diagnostics
  • Akadeum Life Sciences, Inc.
  • BIOCEPT, Inc.
  • BioFluidica, Inc.
  • Biolidics Ltd.
  • Creativ MicroTech, Inc.
  • Epic Sciences
  • Fluxion Biosciences, Inc.
  • Ikonisys Inc.
  • LineaRx, Inc.（Applied DNA Sciences）
  • LungLife AI, Inc.
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • OncoDiscover
  • Precision Medicine Group, LLC.
  • Sysmex Corporation
  • ScreenCell
  • STEMCELL Technologies, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 2. GLOBAL CTC DETECTION AND ENRICHMENT METHODS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL CTC DIRECT DETECTION METHODS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CTC ANALYSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 6. GLOBAL CIRCULATING TUMOR CELLS KITS AND REAGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CIRCULATING TUMOR CELLS BLOOD COLLECTION TUBES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CIRCULATING TUMOR CELLS DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 10. GLOBAL CIRCULATING TUMOR CELLS FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CIRCULATING TUMOR CELLS FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CIRCULATING TUMOR CELLS FOR RESEARCH AND ACADEMIC INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CIRCULATING TUMOR CELLS FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 19. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 23. ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 2. GLOBAL CTC DETECTION AND ENRICHMENT METHODS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL CTC DIRECT DETECTION METHODS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CTC ANALYSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
  • 6. GLOBAL CIRCULATING TUMOR CELLS KITS AND REAGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL CIRCULATING TUMOR CELLS BLOOD COLLECTION TUBES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CIRCULATING TUMOR CELLS DEVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY END USERS, 2022 VS 2030 (%)
  • 10. GLOBAL CIRCULATING TUMOR CELLS FOR HOSPITALS and CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CIRCULATING TUMOR CELLS FOR RESEARCH AND ACADEMIC INSTITUTES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CIRCULATING TUMOR CELLS FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. US CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. CANADA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. UK CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. FRANCE CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. GERMANY CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. ITALY CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF EUROPE CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. INDIA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CHINA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. JAPAN CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SOUTH KOREA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. LATIN AMERICA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027752

Title: Global Circulating Tumor Cells Market Size, Share & Trends Analysis Report by Technology (CTC Detection and Enrichment Methods, CTC Direct Detection Methods, and CTC Analysis), by Product (Kits and Reagents, Blood Collection Tubes and Devices), and by End Users (Hospitals and Clinics, Research and Academic Institutes and Diagnostic Centers),Forecast Period (2023-2030).

Global circulating tumor cells market is anticipated to grow at a CAGR of 12.5% during the Forecast Period (2023-2030). Circulating tumor cells (CTC) provide a blood biomarker for early carcinogenesis, cancer progression, and treatment effectiveness. The growing adoption of CTC assays has attracted intense interest as a biomarker that may assist in disease management and is acting as a key supporting factor for the growth of the market globally. Various test offers physicians the ability to serially monitor their patients' response to treatment, especially for circulating tumor monitoring assay, using a simple blood draw, and using those insights to make informed decisions for future care. Hence, the market players are also focusing on introducing circulating tumor cell-based monitoring assays that further bolster market growth. For instance, in January 2023, Foundation Medicine, Inc., in molecular profiling for cancer, and Natera, Inc., in cell-free DNA testing, launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.

Segmental Outlook

The global circulating tumor cells market is segmented on the technology, product, and end users. Based on the technology, the market is sub-segmented into CTC detection and enrichment methods, CTC direct detection methods, and CTC analysis. Based on the product, the market is sub-segmented into kits and reagents, blood collection tubes, and devices. Further, based on end users, the market is sub-segmented into hospitals and clinics, research and academic institutes, and diagnostic centers. Among the technology, the CTC detection and enrichment methods sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of nanotechnology, microfluidic chips modified with functionalized nanomaterials which are widely used in the enrichment and detection of CTCs.

The Kits and Reagents Sub-Segment is Anticipated to Hold a Considerable Share of the Global Circulating Tumor Cells Market

Among the products, the kits and reagents sub-segment is expected to hold a considerable share of the global circulating tumor cells (CTC) market. The segmental growth is attributed to the growing influence of the non-invasive culture medium kit and reagents in the detection of cancer. Tumor cells derived from individual patients - hold promise in helping improve clinical trial success rates by enabling researchers to better model disease and predict patient response to therapeutics in vitro. Companies' new off-the-shelf, modular tumoroid culture medium kit is designed to make complex cancer models more accessible to researchers. For instance, in June 2023, Thermo Fisher Scientific, in serving science, launched the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications.

Regional Outlook

The global circulating tumor cells market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a considerable CAGR owing to the adoption of effective diagnostic tools such as CTC-based tests and non-invasive methods for the diagnosis of circulating tumors. The key market players include AnchorDx, Burning Rock Biotech Ltd., Exact Sciences Corp., Guardant Health, Otsuka Pharmaceutical Co., Ltd., and others.

The North America Region is Expected to Dominant in the Global Circulating tumor cells Market

Among all regions, the North American region is anticipated to have the largest market share over the forecast period. Regional growth is attributed to the presence of a large patient population, strong presence of key players, ease of drug availability, well-developed healthcare infrastructure, favorable reimbursement policies in the healthcare system, a higher number of researches, development, & innovation activities and higher adoption of advanced circulating tumor cells (CTC) technology. Regional growth is attributed to an increase in cancer patients.

According to the American Cancer Society (ACS), in January 2023, About 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and about 127,070 mortality from lung cancer (67,160 in men and 59,910 in women). The rise in investment by key market players in the region, along with the rise in the adoption of various strategies by the key players is anticipated to increase opportunities in the market. The key market players include Advanced Cell Diagnostics, Bio-Rad Laboratories, Inc., Epic Sciences, Ikonisys Inc., Illumina, Inc., and others.

Market Players Outlook

The major companies serving the circulating tumor cells market include: Bio-Rad Laboratories, Inc., Illumina, Inc., Johnson & Johnson, QIAGEN N.V., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, Epic Sciences, Inc. and Predicine, Inc. entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine's ctDNA-based testing and Epic's CTC-based testing. Epic's CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR, and other phenotypic tests.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global circulating tumor cells market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bio-Rad Laboratories, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. QIAGEN N.V.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Johnson & Johnson Service Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Illumina, Inc.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Circulating Tumor Cells Market by Technology
    • 4.1.1. CTC Detection and Enrichment Methods
    • 4.1.2. CTC Direct Detection Methods
    • 4.1.3. CTC Analysis
  • 4.2. Global Circulating Tumor Cells Market by Product
    • 4.2.1. Kits and Reagents
    • 4.2.2. Blood Collection Tubes
    • 4.2.3. Devices
  • 4.3. Global Circulating Tumor Cells Market by End Users
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Centers
    • 4.3.3. Research and Academic Institutes

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advanced Cell Diagnostics
  • 6.2. Akadeum Life Sciences, Inc.
  • 6.3. BIOCEPT, Inc.
  • 6.4. BioFluidica, Inc.
  • 6.5. Biolidics Ltd.
  • 6.6. Creativ MicroTech, Inc.
  • 6.7. Epic Sciences
  • 6.8. Fluxion Biosciences, Inc.
  • 6.9. Ikonisys Inc.
  • 6.10. LineaRx, Inc. (Applied DNA Sciences)
  • 6.11. LungLife AI, Inc.
  • 6.12. Menarini Silicon Biosystems
  • 6.13. Miltenyi Biotec
  • 6.14. OncoDiscover
  • 6.15. Precision Medicine Group, LLC.
  • 6.16. Sysmex Corporation
  • 6.17. ScreenCell
  • 6.18. STEMCELL Technologies, Inc.